150 Participants Needed

Thulium Fiber Laser for Kidney Stones

(TFL Trial)

NB
KB
Overseen ByKahina Bensaadi, DESS
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 2 JurisdictionsThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

This is a multi-center, prospective clinical trial to assess the effect of TFL for the lithotripsy of kidney stones.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the Thulium Fiber Laser treatment for kidney stones?

Research shows that the Thulium Fiber Laser (TFL) is effective in breaking down small kidney stones with low complication rates. It has advantages like higher absorption, smaller fibers, and better pulse rate compared to other lasers, making it a promising option for treating kidney stones.12345

Is the Thulium Fiber Laser safe for treating kidney stones?

The Thulium Fiber Laser (TFL) has been studied for safety in treating kidney stones, showing it is generally safe with some minor complications. In one study, 61.8% of patients experienced mild postoperative issues, but no major equipment failures occurred during procedures.12678

How does the Thulium Fiber Laser treatment for kidney stones differ from other treatments?

The Thulium Fiber Laser (TFL) is unique because it uses a specific wavelength (1.94 μm) that allows for more precise and efficient stone fragmentation with less retropulsion (movement of the stone during treatment) compared to traditional lasers like the Holmium:YAG. It also uses smaller fibers, which can be beneficial in accessing challenging areas like lower pole kidney stones.12456

Research Team

BHOJANI, Naeem | CHUM

Naeem Bhojani, MD

Principal Investigator

Centre hospitalier de l'Université de Montréal (CHUM)

Eligibility Criteria

This trial is for adults who can consent to treatment, have kidney stones between 8-20 mm in size suitable for ureteroscopy, and meet specific health guidelines. It's not open to those with neurogenic bladder conditions, spinal cord injuries, pregnancy, untreated UTIs or a history of certain urinary tract procedures.

Inclusion Criteria

I am having a procedure to look inside my ureters, but only one side will be studied.
I am considered fit for a specific kidney stone removal surgery.
I have a kidney stone or multiple stones that together are 8-20 mm in size.
See 2 more

Exclusion Criteria

I currently have a urinary tract infection that hasn't been treated.
I have a bladder condition due to nerve problems or a spinal cord injury.
I have stones in my ureter.
See 3 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Ureteroscopy with lithotripsy using the Thulium Fiber Laser

1 day
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

6 weeks
Medical chart review and post-operative CT imaging

Treatment Details

Interventions

  • Thulium Fiber Laser
Trial OverviewThe study is evaluating the effectiveness of Thulium Fiber Laser (TFL) technology in breaking down kidney stones during ureteroscopy—a procedure where a small scope is used to locate and remove stones from the urinary tract.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: LithotripsyExperimental Treatment1 Intervention
Ureteroscopy with lithotripsy using the Thulium Fiber Laser

Thulium Fiber Laser is already approved in United States, European Union for the following indications:

🇺🇸
Approved in United States as Thulium Fiber Laser for:
  • Kidney stone lithotripsy
🇪🇺
Approved in European Union as Thulium Fiber Laser for:
  • Kidney stone lithotripsy

Find a Clinic Near You

Who Is Running the Clinical Trial?

Centre hospitalier de l'Université de Montréal (CHUM)

Lead Sponsor

Trials
389
Recruited
143,000+

Mayo Clinic

Collaborator

Trials
3,427
Recruited
3,221,000+

University of California, San Diego

Collaborator

Trials
1,215
Recruited
1,593,000+

Columbia University

Collaborator

Trials
1,529
Recruited
2,832,000+

University of British Columbia

Collaborator

Trials
1,506
Recruited
2,528,000+

Vanderbilt University

Collaborator

Trials
714
Recruited
6,143,000+

The Cleveland Clinic

Collaborator

Trials
1,072
Recruited
1,377,000+

Ohio State University

Collaborator

Trials
891
Recruited
2,659,000+

Findings from Research

The SuperPulse Thulium fiber laser (SP TFL) is an effective and safe treatment for small calyceal stones in the lower pole of the kidney, achieving a stone-free rate of 86.6% after 90 days in a study of 15 patients.
The use of small laser fibers allows for better maneuverability during flexible ureteroscopy, enabling successful treatment even in challenging anatomical conditions, with a low complication rate of 6.6%.
[Flexible ureteroscopy for lower pole renal stones: novel superpulse thulium (TM) fiber laser lithotripsy].Rapoport, LM., Gazimiev, MA., Korolev, DO., et al.[2021]
In a study of 126 pediatric patients undergoing retrograde intrarenal surgery for kidney stones, both thulium fiber laser (TFL) and high-power Holmium:YAG laser were found to be safe and effective, with similar stone-free rates (81.4% for Holmium:YAG vs. 89.7% for TFL).
The TFL group had a significantly shorter operative time (49.5 minutes) and a lower re-intervention rate (6.89%) compared to the Holmium:YAG group (64.3 minutes and 14.4%, respectively), suggesting TFL may offer advantages in surgical efficiency.
Comparing outcomes of thulium fiber laser versus high-power Holmium:YAG laser lithotripsy in pediatric patients managed with RIRS for kidney stones. A multicenter retrospective study.Candela, L., Solano, C., Castellani, D., et al.[2023]
The thulium fiber laser (TFL) significantly reduced stone disintegration time in the miniaturized percutaneous nephrolithotomy (Miniperc) procedure, averaging 11 minutes compared to 20 minutes with the holmium laser, indicating greater efficiency in treating renal stones.
While TFL showed a higher stone-free rate (94.9% vs. 90.9% for holmium), it was associated with a higher incidence of self-limiting postoperative hematuria, suggesting a trade-off between efficacy and safety.
Thulium fiber laser versus holmium:yttrium aluminum garnet laser for stone lithotripsy during mini-percutaneous nephrolithotomy: A prospective randomized trial.Mahajan, AD., Mahajan, SA.[2022]

References

1.Russia (Federation)pubmed.ncbi.nlm.nih.gov
[Flexible ureteroscopy for lower pole renal stones: novel superpulse thulium (TM) fiber laser lithotripsy]. [2021]
Comparing outcomes of thulium fiber laser versus high-power Holmium:YAG laser lithotripsy in pediatric patients managed with RIRS for kidney stones. A multicenter retrospective study. [2023]
Thulium fiber laser versus holmium:yttrium aluminum garnet laser for stone lithotripsy during mini-percutaneous nephrolithotomy: A prospective randomized trial. [2022]
Super pulsed thulium fiber laser outcomes in retrograde intrarenal surgery for ureteral and renal stones: a systematic review and meta-analysis. [2023]
Ex vivo testing of air-cooled CW/modulated 30 W thulium fiber laser for lithotripsy. [2019]
Collateral damage to the ureter and Nitinol stone baskets during thulium fiber laser lithotripsy. [2016]
[Efficacy and safety of superpulse thulium laser lithotripsy in the intracavitary treatment of urinary calculi]. [2023]
The clinical efficiency and safety of 60W superpulse thulium fiber laser in retrograde intrarenal surgery. [2022]